2015财年GDUFA自我认定临近
出自识林
2015财年GDUFA自我认定临近
笔记 2014-04-30 Lachman CONSULTANTS 当你以为一切都已经完成时,是时候重做一遍了。FDA公布仿制药申请中新的场地自我认定(Self-Identify)很快将再次开始。FDA公告规定: 请注意以下要点: 请注意,根据联邦食品、药品和化妆品法案第510节(21 U.S.C. § 360)的注册和登记是与GDUFA的自我认定不同的过程。因此需要许多人分别提交信息到各自的系统。每个系统需要填充自己的数据库以满足特殊要求和截至日期。但是,两者建立在相同的平台上并基于相同的技术标准。 因此,为了完全弄清楚,再说一次。由于许多设施是非GDUFA付费支付的,需要进行设施及产品的注册和登记。自我认定过程是用于跟踪缴付费用的机构,以及鉴定可能被豁免收费但仍需要根据一般程序进行检查的设施。 似乎是重复的?是的,但是直到FDA计算机系统在某种程度上实现无缝交流,否则企业将需要继续使用FDA提供的现有基础设施和软件填写不同的数据库。祝好运,另外不要忘记,4月15日(美国报税的截止日期)来了又过去,FDA的追税人来了。 Lachman CONSULTANTS - Bob Pollock先生 2014-04-29 Guess What? It's Almost Time to Self-Identify under GDUFA for FY 2015 Just when you thought you got it all done, it is time to do it all over again. FDA announced that the new self-identification for facilities named in a generic drug application will begin again soon. The FDA announcement states: And very importantly please note the following: Please note that registration and listing under section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360) is a different process than self-identification under GDUFA. Many persons will thus be required to submit information separately to the respective systems. Each system populates its own database to meet unique requirements and deadlines. Both, however, are built on the same platform and based on the same technical standards. So to make this perfectly clear, once is not enough. Facility and product listing and registration need to be conducted as many facilities are non-GDUFA fee paying. The self-identification process is used to keep track of the fee paying organizations, as well as identify facilities that may be fee exempt, but may still need to be inspected under the generic program. Seems like duplication? Yes, it is, but, until the FDA computer systems all speak to each other in a manner that is seamless, the industry will need to continue to populate these various databases using the existing infrastructure and software that FDA makes available. Good luck and, don’t forget, now that April 15 has come and gone, the FDA tax man commeth. 岗位必读建议:
文件适用范围: 要点总结:
以上仅为部分要点,请阅读原文,深入理解监管要求。 岗位必读建议
文件适用范围本文适用于在美国进行药品和设备生产的企业,包括化学药、生物制品、原料药等,不包括中药或疫苗。适用于所有在美国注册分类下的创新药、仿制药、生物类似药等。发布机构为美国,适用于Biotech、大型药企、跨国药企等各类企业。 要点总结
以上仅为部分要点,请阅读原文,深入理解监管要求。 岗位必读建议
文件适用范围本文适用于美国市场的所有化学仿制药,包括原料药和成品药,由美国食品药品监督管理局(FDA)发布,适用于各类药企,包括Biotech、大型药企、跨国药企等。 文件要点总结
以上仅为部分要点,请阅读原文,深入理解监管要求。 |